THZ2 (CDK7-IN-1) is a potent and selective CDK7 inhibitor derived from THZ1, exhibiting an IC50 of 13.9 nM. It is a research tool for investigating CDK7s role in transcription and cell cycle progression, with studies demonstrating its potential efficacy in models of triple-negative breast cancer (TNBC) both in vitro and in vivo.